Benitz W E, Kelley R T, Anderson C M, Lorant D E, Bernfield M
Department of Pediatrics, Stanford University School of Medicine, CA 94305.
Am J Respir Cell Mol Biol. 1990 Jan;2(1):13-24. doi: 10.1165/ajrcmb/2.1.13.
Proliferation of smooth muscle cells is an important component of pulmonary arterial morphogenesis, both during normal development and pathologic remodeling. However, little is known of the factors that regulate smooth muscle proliferation in these vessels. To investigate the hypothesis that factors produced by endothelial cells may regulate smooth muscle cell growth, we studied the effects of culture medium conditioned by fetal bovine pulmonary arterial endothelium on proliferation of smooth muscle cells in culture. This conditioned medium contains an inhibitor of smooth muscle proliferation that is degraded by nitrous acid, heparinase, and heparitinase, but resists degradation by protease, boiling, and chondroitin ABC lyase, indicating that the inhibitor is structurally similar to heparin. Inhibitor release occurs in both growing and confluent endothelial cell cultures and in the presence and absence of serum. A growth-inhibiting proteoglycan purified to homogeneity from endothelial cell-conditioned medium has physicochemical characteristics similar to those of the prototypic basement membrane heparan sulfate proteoglycan of the Englebreth-Holm-Swarm tumor: an overall size of approximately 10(6) D, heparan sulfate chains of 60,000 D, and a buoyant density of 1.33 g/ml. Antibody raised against the tumor basement proteoglycan recognizes this endothelial heparan sulfate proteoglycan, and Western blotting after SDS-PAGE demonstrates that the core proteins of both proteoglycans migrate as a doublet at apparent molecular weights of 450,000 and 360,000 D. Heparan sulfate glycosaminoglycan prepared from purified medium proteoglycan is a potent inhibitor of smooth muscle cell growth, exhibiting activity approximately 1,000 times greater than that of heparin. These results indicate that endothelial cells cultured from fetal bovine pulmonary arteries produce a basement membrane heparan sulfate proteoglycan that is a potent inhibitor of smooth muscle proliferation. This proteoglycan may mediate endothelial regulation of smooth muscle growth during development or pathologic pulmonary arterial remodeling.
平滑肌细胞增殖是肺动脉形态发生的重要组成部分,无论是在正常发育过程中还是病理重塑过程中。然而,对于调节这些血管中平滑肌增殖的因素知之甚少。为了研究内皮细胞产生的因子可能调节平滑肌细胞生长这一假说,我们研究了胎牛肺动脉内皮细胞条件培养基对培养的平滑肌细胞增殖的影响。这种条件培养基含有一种平滑肌增殖抑制剂,该抑制剂可被亚硝酸、肝素酶和硫酸乙酰肝素酶降解,但能抵抗蛋白酶、煮沸和软骨素ABC裂解酶的降解,表明该抑制剂在结构上与肝素相似。抑制剂的释放发生在生长和汇合的内皮细胞培养物中,以及有无血清的情况下。从内皮细胞条件培养基中纯化至同质的一种生长抑制蛋白聚糖,其物理化学特性与Englebreth-Holm-Swarm肿瘤的原型基底膜硫酸乙酰肝素蛋白聚糖相似:总体大小约为10(6)D,硫酸乙酰肝素链为60,000D,浮力密度为1.33g/ml。针对肿瘤基底蛋白聚糖产生的抗体可识别这种内皮硫酸乙酰肝素蛋白聚糖,SDS-PAGE后的蛋白质印迹显示,两种蛋白聚糖的核心蛋白均以450,000和360,000D的表观分子量呈双峰迁移。从纯化的培养基蛋白聚糖制备的硫酸乙酰肝素糖胺聚糖是平滑肌细胞生长的有效抑制剂,其活性比肝素高约1000倍。这些结果表明,从胎牛肺动脉培养的内皮细胞产生一种基底膜硫酸乙酰肝素蛋白聚糖,它是平滑肌增殖的有效抑制剂。这种蛋白聚糖可能在发育或病理性肺动脉重塑过程中介导内皮细胞对平滑肌生长的调节。